CALM Study: Tight Control with Anti-TNF Wins in Crohn's Disease

Save

Not unlike rheumatoid arthritis and other inflammatory disorders, therapeutic efficacy in Crohn's disease (CD) is often assessed clinically. There is growing use and interest in biomarkers of intestinal inflammation, such as faecal calprotectin and C-reactive protein.

Biosimilars Projected to Yield $54 Billion in Savings

Save

A primary projected advantage to biosimilar drugs development has been cost savings. A new study from the RAND Corporation suggests biosimilars could cut health care spending in the United States by $54 billion over the next decade. This number is nearly 20 percent greater than a similar study conducted three years ago by the same researchers. 

Stelara FDA Approved for Use in Adolescent Psoriasis

Save

Johnson & Johnson has announced that they have received an expanded FDA approval for the use of ustekinumab (Stelara) in treating adolescent patients, aged 12 and over, with moderate to severe plaque psoriais.

IBD Associated with Increased risk of Autoimmune and Inflammatory Diseases

Save

A registry based study has shown higher rates of immune mediated diseases (IMD) in patients with inflammatory bowel disease (IBD).

Safety of Long-Term PPI Use

Save

The current issue of JAMA reviews the safety of long-term use of proton pump inhibitors (PPI). The following is a collection of the evidence about these purported risks.

Fractures

15 September 2017 The RheumNow Week in Review

Save

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report discusses metabolic syndrome in lupus, bisphosphonate holidays, vasculitis and vascular inflammation, vaccination, and the repeated wonders of Vitamin D.

New Recommendations on Biosimilar Use

Save

The introduction of a growing number of biosimilars into the market poses a substantial change in cost of care for patients with inflammatory rheumatologic disorders.  

Adalimumab Biosimilars Adding Up

Save

Reuters reports that yet another adalimumab biosimilar has been approved by European Union regulators.

The new drug is named Imraldi, and is manufactured by Samsung Bioepis, a company who has several biosimilars approved or in development for worldwide use.

Kids with Crohn's have Profound MSK Deficits - but No Increase in Fractures

Save

Crohn’s disease (CD), a chronic inflammatory condition of the gastrointestinal tract, is also known for its propensity to affect the musculoskeletal system.

Pediatric Consensus on Comorbidity Assessments

Save

Comorbidity is a serious consequence or confounder in patients with inflammatory diseases. This has been well described in both psoriatic and rheumatoid disease.

NOR-SWITCH Study Validates Biosimilar Use in Multiple Indications

Save

Lancet reports the results of the NOR-SWITCH study - a trial performed in Norway as biosimilars were being introduced.

NSAIDs Increase Risk of Acute Myocardial Infarction

Save

Using data from Canadian and European healthcare databases, the BMJ has reported that all NSAIDs, including celecoxib and naproxen, increase the risk of acute myocardial infarction.

Increased Comorbidities in Rheumatoid Arthritis

Save

A population based study from Taiwan examined the frequencies of comorbidities in a rheumatoid arthritis (RA) population.

Tofacitinib Effective in Ulcerative Colitis

Save

Tofacitinib is currently approved for use in rheumatoid arthritis, but is being studied in numerous other inflammatory conditons including spondylitis, psoriasis, and psoriatic arthritis, and has also been studied in patients with ulcerative colitis (UC).

Venous Thromboembolism Risk Factors in ANCA-Associated Vasculitis

Save

A retrospective analysis of four European vasculitis trials analyzes the risk venous thromboembolism (VTE) with ANCA-associated vasculitis and shows that CRP, cutaneous and GI involvement and baseline creatinine were most associated with VTE risk.

Anti-IL-23 Therapy Effective in Crohn's Disease

Save

Lancet has reported the results of risankizumab, an interleukin-23 (IL-23) inhibitor, in Crohn's disease. Risankizumab is a humanised monoclonal antibody targeting the p19 subunit of interleukin-23, and is being developed for Crohn's disease.

Celecoxib Plus PPI Preferred in High Risk Patients

Save

When do the risks outweigh the benefits of NSAIDs use, especially in those with prior cardiovascular and gastrointestinal events? The CONCERN study has tested the effects of proton-pump inhibitor (PPI) in preventing GI bleeds when using NSAIDs and ASA.

The RheumNow Week in Review – 31 March 2017

Save

Dr. Jack Cush reviews highlights from the news and Advances in Targeted Therapies meeting in Mandelieu, France:

Tweeting this week from Advances in Targeted Therapies #ATT2017 in Mandelieu, France.

TNF Inhibitor Induced Psoriasis

Save

Tumor necrosis factor-α inhibitors (TNFi) rarely have been reported to induce new-onset psoriasis.

Alcohol Use During Methotrexate Studied

Save

A recent RheumNow survey of 495 rheumatologists found that half of rheumatologists allow 1-3 alcoholic drinks per week and 6-7% has no alcohol restrictions while being treated with methotrexate (MTX).